Published in J Immunol on June 01, 2001
Evidence of a large-scale functional organization of mammalian chromosomes. PLoS Genet (2005) 2.73
Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol (2003) 2.67
The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med (2002) 2.37
Host responses in tissue repair and fibrosis. Annu Rev Pathol (2012) 2.10
Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol (2007) 2.02
Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature (2008) 1.88
Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med (2009) 1.74
Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol (2006) 1.59
FcγRI mediates serum amyloid P inhibition of fibrocyte differentiation. J Leukoc Biol (2012) 1.54
Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells. Proc Natl Acad Sci U S A (2008) 1.48
Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis (2005) 1.48
Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog (2007) 1.46
Pentraxins: structure, function, and role in inflammation. ISRN Inflamm (2013) 1.23
Pattern recognition by pentraxins. Adv Exp Med Biol (2009) 1.19
Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein. Proc Natl Acad Sci U S A (2011) 1.04
Pathogen recognition by the long pentraxin PTX3. J Biomed Biotechnol (2011) 0.94
SAP suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. Immunol Cell Biol (2011) 0.92
Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease. PLoS One (2011) 0.89
Hepatocytes: a key cell type for innate immunity. Cell Mol Immunol (2015) 0.86
Signaling mechanisms of enhanced neutrophil phagocytosis and chemotaxis by the polysaccharide purified from Ganoderma lucidum. Br J Pharmacol (2003) 0.86
Serum amyloid P inhibits granulocyte adhesion. Fibrogenesis Tissue Repair (2013) 0.86
Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcγ receptors. Curr Opin Organ Transplant (2011) 0.86
Persistent lung inflammation and fibrosis in serum amyloid P component (APCs-/-) knockout mice. PLoS One (2014) 0.85
A serum amyloid P-binding hydrogel speeds healing of partial thickness wounds in pigs. Wound Repair Regen (2009) 0.85
The "sweet" side of a long pentraxin: how glycosylation affects PTX3 functions in innate immunity and inflammation. Front Immunol (2013) 0.85
Distinct Fcγ receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibrocyte differentiation. J Immunol (2014) 0.83
The long pentraxin PTX3 promotes fibrocyte differentiation. PLoS One (2015) 0.82
Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics Clin Appl (2012) 0.81
Identification of calcium-binding proteins associated with the human sperm plasma membrane. Reprod Biol Endocrinol (2010) 0.80
New approaches to modulating idiopathic pulmonary fibrosis. Curr Allergy Asthma Rep (2013) 0.79
Absence of FcγRIII results in increased proinflammatory response in FcγRIII-KO cardiac recipients. Transplantation (2013) 0.78
Human SAP is a novel peptidoglycan recognition protein that induces complement-independent phagocytosis of Staphylococcus aureus. J Immunol (2013) 0.78
Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis. Clin Immunol (2016) 0.76
Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease. JCI Insight (2016) 0.75
Fcγ Receptors in Solid Organ Transplantation. Curr Transplant Rep (2016) 0.75
Recapitulation of Candidate Systemic Lupus Erythematosus-Associated Variants in Koreans. Genomics Inform (2016) 0.75
Protective molecules and their cognate antibodies: new players in autoimmunity. Auto Immun Highlights (2010) 0.75
Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 3.42
C-reactive protein and the acute phase response. Adv Intern Med (1982) 2.20
C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med (1981) 2.17
The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med (1999) 1.84
Regulation of complement activation by C-reactive protein. Immunopharmacology (1999) 1.78
Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis. Clin Exp Immunol (1981) 1.48
C-reactive protein binds to Fc gamma RI in transfected COS cells. J Immunol (1995) 1.44
Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J Immunol (2001) 1.44
C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest (2000) 1.42
Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c. Proc Natl Acad Sci U S A (1982) 1.33
Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J Immunol (1996) 1.27
Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest (1993) 1.15
Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack. J Immunol (2000) 1.14
Inhibition of the alternative pathway of human complement by structural analogues of sialic acid. J Immunol (1988) 1.13
Opsonic properties of C-reactive protein in vivo. J Immunol (1982) 1.13
C-reactive protein reactivity with complement and effects on phagocytosis. Ann N Y Acad Sci (1982) 1.10
C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol (1983) 1.08
Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol (1992) 1.07
A role for C-reactive protein in the complement-mediated stimulation of human neutrophils by type 27 Streptococcus pneumoniae. J Immunol (1982) 1.07
Decreased autoantibody levels and enhanced survival of (NZB x NZW) F1 mice treated with C-reactive protein. Clin Immunol Immunopathol (1994) 1.07
Interaction of C-reactive protein with liposomes. III. Membrane requirements for binding. J Immunol (1981) 1.06
C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. J Immunol (1984) 1.06
C-reactive protein binding to murine leukocytes requires Fc gamma receptors. J Immunol (2000) 1.06
C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J Immunol (1991) 1.03
The role of the spleen in the protective effect of C-reactive protein in Streptococcus pneumoniae infection. Clin Exp Immunol (1983) 1.02
Requirement for human red blood cells in inactivation of C3b in immune complexes and enhancement of binding to spleen cells. J Immunol (1983) 1.02
Binding of human C-reactive protein to bacteria. Infect Immun (1982) 1.02
GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy (2004) 1.01
Structure/function studies of human decay-accelerating factor. Immunology (2000) 0.98
Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions. J Immunol (1986) 0.98
Recurrent bacterial infections associated with C3 nephritic factor and hypocomplementemia. N Engl J Med (1983) 0.97
Effect of gangliosides on activation of the alternative pathway of human complement. J Immunol (1988) 0.97
Multiple ligand binding sites on domain seven of human complement factor H. Int Immunopharmacol (2001) 0.96
Complement regulation in innate immunity and the acute-phase response: inhibition of mannan-binding lectin-initiated complement cytolysis by C-reactive protein (CRP). Clin Exp Immunol (1998) 0.96
Effects of calcium, magnesium, and phosphorylcholine on secondary structures of human C-reactive protein and serum amyloid P component observed by infrared spectroscopy. J Biol Chem (1994) 0.93
Inhibitory effect of C-reactive protein on alternative C pathway activation by liposomes and Streptococcus pneumoniae. J Immunol (1981) 0.93
Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis. J Immunol (1986) 0.92
Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differential localization of C3 and stimulation of phagocytosis. J Immunol (1984) 0.91
Effect of C-reactive protein on the complement-mediated stimulated of human neutrophils by Streptococcus pneumoniae serotypes 3 and 6. Infect Immun (1982) 0.91
The role of C-reactive protein in the resolution of bacterial infection. Curr Opin Infect Dis (2001) 0.91
Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J Immunol (1994) 0.90
Mechanism of complement-dependent haemolysis via the lectin pathway: role of the complement regulatory proteins. Clin Exp Immunol (1999) 0.89
The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol (1996) 0.88
Identification of a polypeptide sequence that mediates nuclear localization of the acute phase protein C-reactive protein. J Immunol (1990) 0.86
Alveolar and interstitial macrophage populations in the murine lung. Exp Lung Res (1992) 0.85
Growth of group B streptococci in human serum leads to increased cell surface sialic acid and decreased activation of the alternative complement pathway. Can J Microbiol (1994) 0.85
Expression of rabbit C-reactive protein in transgenic mice. Immunol Cell Biol (1995) 0.85
Quantitative analysis of C4b dimer binding to distinct sites on the C3b/C4b receptor (CR1). J Biol Chem (1994) 0.84
Autoantibodies to cryptic epitopes of C-reactive protein and other acute phase proteins in the toxic oil syndrome. J Autoimmun (1995) 0.84
Limited Wegener's granulomatosis presenting with complete heart block. Scand J Rheumatol (2004) 0.84
Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H. Infect Immun (1998) 0.83
Hyperoxic suppression of Fc-gamma receptor-mediated phagocytosis by isolated murine pulmonary macrophages. Am J Respir Cell Mol Biol (1995) 0.82
Inflammatory potential of C-reactive protein complexes compared to immune complexes. Clin Immunol Immunopathol (1998) 0.81
Betaxolol and drug-induced lupus complicated by pericarditis and large pericardial effusion. West J Med (1997) 0.81
Quantitative analysis of C4Ab and C4Bb binding to the C3b/C4b receptor (CR1, CD35). Clin Exp Immunol (1997) 0.80
C-reactive protein (CRP) binding to the Sm-D protein of snRNPS. Identification of a short polypeptide binding region. Mol Immunol (1993) 0.80
Complement-dependent binding of C-reactive protein complexes to human erythrocyte CR1. Clin Immunol Immunopathol (1996) 0.79
Activation of human complement by liposomes: serum factor requirement for alternative pathway activation. J Immunol (1980) 0.79
Inhibition of antibody responses to phosphocholine by C-reactive protein. J Immunol (1984) 0.79
Chromatin clearance in C57Bl/10 mice: interaction with heparan sulphate proteoglycans and receptors on Kupffer cells. Clin Exp Immunol (1999) 0.78
C3 nephritic factor protects bound C3bBb from cleavage by factor I and human erythrocytes. Mol Immunol (1985) 0.78
A new procedure for the separation of protein Z, prothrombin fragment 1.2 and calreticulin from human plasma. Thromb Res (1991) 0.78
C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. Immunology (1987) 0.77
Monoclonal antibody for DNA measurement in biological fluids. J Immunol Methods (1986) 0.77
Hamster female protein binding to chromatin, histones and DNA. Mol Immunol (1992) 0.77
Expression and radiolabeling of human C-reactive protein in baculovirus-infected cell lines and Trichoplusia ni larvae. Protein Expr Purif (1995) 0.76
Suppressor T cells: presence in mice rendered tolerant by neonatal treatment with anti-receptor antibody or antigen. J Immunol (1977) 0.75
The role of C-reactive protein and polyarginine in tumor immunotherapy. Cancer (1986) 0.75
[Opsonic effect of CRP on the in vivo clearance of sensitized, autologous erythrocytes]. Nihon Jinzo Gakkai Shi (1982) 0.75
Kallmann's syndrome: reproductive success. N J Med (1990) 0.75